Telangiectasia

Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseases

Retrieved on: 
Wednesday, April 3, 2024
Hereditary hemorrhagic telangiectasia, Telangiectasia, Biotechnology, Blood, Disease, Atlas, Patient, Lung, Stroke, Viking Global Investors, Death, Artery, Chiari malformation, Rupture, Intraparenchymal hemorrhage, Heart failure, Lightspeed Venture Partners, Therapy, TGF, Antibody, Bleeding, Heart, Pharmacology, Unified school district, HHT, PAH, Atlas Venture, Pulmonary hypertension, Pharmaceutical industry

CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies, launched today with $128 million in financing. The Series A was co-led by BVF Partners and Atlas Venture, with participation from Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors, Velosity Capital, and Checkpoint Capital. Diagonal was co-founded by Chief Executive Officer, Alex Lugovskoy, Ph.D., and Atlas and previously seeded by Atlas, Lightspeed Venture Partners, and Velosity Capital. The financing will support further advancement of the company’s proprietary DIAGONAL platform and pipeline of novel therapeutics to value-creating milestones, including its lead program for the treatment of hereditary hemorrhagic telangiectasia (HHT), a severely debilitating bleeding disorder with limited therapeutic options, through clinical proof-of-concept. Diagonal's agonist antibody activates a receptor complex in the TGF-β superfamily genetically impaired in HHT patients. In preclinical models of HHT, Diagonal's agonist antibodies prevent and reverse the formation of pathological vascular malformations.

Key Points: 
  • Diagonal was co-founded by Alex Lugovskoy, Ph.D., and Atlas and previously seeded by Atlas, Lightspeed Venture Partners, and Velosity Capital.
  • CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies, launched today with $128 million in financing.
  • Diagonal was co-founded by Chief Executive Officer, Alex Lugovskoy, Ph.D., and Atlas and previously seeded by Atlas, Lightspeed Venture Partners, and Velosity Capital.
  • In preclinical models of HHT, Diagonal's agonist antibodies prevent and reverse the formation of pathological vascular malformations.

Orphan designation: 6-(4-(1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one, L-tartrate salt Treatment of hereditary haemorrhagic telangiectasia, 20/03/2023 Positive

Retrieved on: 
Sunday, February 4, 2024
COMP, IRIS, European Commission, Telangiectasia, Committee, Patient, EMA, Pharmaceutical industry

Key facts

Key Points: 
  • Key facts
    - Active substance
    - 6-(4-(1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one, L-tartrate salt
    - Intended use
    - Treatment of hereditary haemorrhagic telangiectasia
    - Orphan designation status
    - Positive
    - EU designation number
    - EU/3/23/2766
    - Date of designation
    - Sponsor
    FGK Representative Service GmbH
    Patients' organisations
    For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
    European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:
    EMA list of opinions on orphan medicinal product designation
    EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

Can I put cortisone on my face? The right advice on creams to fix irritated skin

Retrieved on: 
Tuesday, June 20, 2023
Rosacea, Human, Skin, Vein, Atrophoderma, Education, Face, Solution, Dermatitis, Connective tissue, Telangiectasia, Finger, Cortisone, Acne, Research, Psoriasis, Capillary, Perioral dermatitis, Hydrocortisone, Erythema, Patient, Risk, Steroid, Vitiligo, Sunburn, Glycosaminoglycan, Groin, Maharashtra University of Health Sciences, News, Red, Sulfur, Vaccine, Dietary supplement, Mineral oil, Cosmetics, Topical medication

Topical corticosteroids, also referred to as corticosteroids or cortisone, are the go-to treatment for many skin disorders including eczema, dermatitis and psoriasis.

Key Points: 
  • Topical corticosteroids, also referred to as corticosteroids or cortisone, are the go-to treatment for many skin disorders including eczema, dermatitis and psoriasis.
  • They can be found in various forms such as creams, ointments, and solutions.
  • Topical corticosteroids come in different strengths, from mild (such as 0.5% Hydrocortisone, available over the counter) to very potent prescription formulations.

‘Use sparingly’

    • Such warnings ignore the fact many patients are prescribed modest-strength topical steroids, which are safe and effective when used properly.
    • From the patient’s perspective, the current warnings lump all steroids together regardless of their potential for side effects.

Mixed messages

    • Or hit the problem hard with a stronger concentration for less time?
    • If cortisone is extensively used, it is advised adults and children should be examined yearly for side effects.
    • Skin atrophy (or deterioration) is the most common side effect of topical corticosteroids and manifests as tiny degenerative alterations within a few weeks.

Skin thinning

    • Repeated use in the same spot on the body results in alterations to the skin’s connective tissue and epidermal thinning.
    • That can result in lax, translucent, wrinkled skin as well as striae (stretch marks), fragility, hypo-pigmentation (fading) and the prominence of underlying veins.
    • The good news is that once topical corticosteroids are stopped, short-term atrophy from treatment can be reversed, although skin normalisation may take months.

Can you use it safely on your face?

    • Using strong cortisone creams or ointments on the face can lead to steroid dependence.
    • Topical steroids on the face can cause symptoms sometimes referred to as “red face syndrome”, dermatitis rosaceaformis steroidica or steroid addiction.
    • And stopping steroid use on the face after an extended period can have considerable rebound effects including erythema (redness), burning and scaling.

The bottom line

    • To avoid skin damage, corticosteroids should only be used on skin affected by a skin disease.
    • Finally, treatment should be customised based on the person’s symptoms, the body parts affected and how long treatment might be required.
    • This article reflects the views of the author and
      should not be construed to represent views or
      policies.

Lutris Pharma Presents Data From a Real-World Analysis of Skin Toxicity From EGFR Inhibitors - an Unmet Challenge, at the 2023 American Academy of Dermatology Annual Meeting

Retrieved on: 
Friday, March 17, 2023
Database, Arthritis, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Trinity, IQVIA, Xeroderma, Telangiectasia, Department of Medicine – University of Pamplona, Clinical trial, Medicine, State university system, Cancer, American Academy, Toxicity, Skin condition, Paronychia, Bangladesh Technical Education Board, TEL, Trichomegaly, State University of New York Upstate Medical University, Patient, AAD, EGFR, American Academy of Dermatology, Hyperpigmentation, Human musculoskeletal system, Poster, FDA, Rash, NIH, Skin, Pharmaceutical industry, Lutris

The analysis was supported, in part, by Lutris Pharma and the intramural research program of the National Institutes of Health (NIH).

Key Points: 
  • The analysis was supported, in part, by Lutris Pharma and the intramural research program of the National Institutes of Health (NIH).
  • While such patients are commonly treated prophylactically with antibiotics, there is insufficient evidence to support its practice, leading to a significant unmet medical need."
  • EGFR inhibitors are approved for the treatment of multiple epithelial tumors and can be either biologics or small molecules.
  • The poster will be available after the event on the "Events and Presentations" section of Lutris' website at: https://www.lutris-pharma.com/events-and-presentations/

Lutris Pharma Presents Data From a Real-World Analysis of Skin Toxicity From EGFR Inhibitors - an Unmet Challenge, at the 2023 American Academy of Dermatology Annual Meeting

Retrieved on: 
Friday, March 17, 2023
Database, Arthritis, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Trinity, IQVIA, Xeroderma, Telangiectasia, Department of Medicine – University of Pamplona, Clinical trial, Medicine, State university system, Cancer, American Academy, Toxicity, Skin condition, Paronychia, Bangladesh Technical Education Board, TEL, Trichomegaly, State University of New York Upstate Medical University, Patient, AAD, EGFR, American Academy of Dermatology, Hyperpigmentation, Human musculoskeletal system, Poster, FDA, Rash, NIH, Skin, Pharmaceutical industry, Lutris

The analysis was supported, in part, by Lutris Pharma and the intramural research program of the National Institutes of Health (NIH).

Key Points: 
  • The analysis was supported, in part, by Lutris Pharma and the intramural research program of the National Institutes of Health (NIH).
  • While such patients are commonly treated prophylactically with antibiotics, there is insufficient evidence to support its practice, leading to a significant unmet medical need."
  • EGFR inhibitors are approved for the treatment of multiple epithelial tumors and can be either biologics or small molecules.
  • The poster will be available after the event on the "Events and Presentations" section of Lutris' website at: https://www.lutris-pharma.com/events-and-presentations/

Advalight Partners with Dr. Daniel Barrett to Provide Great Results with Minimal Downtime with the ADVATx

Retrieved on: 
Wednesday, February 1, 2023
Nose, Physician, Acne, Dyschromia, Laser, Smash Mouth, Patient, Face, Skin, Melasma, Scar, Hemangioma, Dermatology, Telangiectasia, Hyperpigmentation, Rosacea, Medical device, Cosmetics

Dr. Barrett's passion for results with minimal downtime perfectly aligns with ADVATx's technology and the incredible results we continue to see."

Key Points: 
  • Dr. Barrett's passion for results with minimal downtime perfectly aligns with ADVATx's technology and the incredible results we continue to see."
  • "My practice is touted for providing natural looking results using the most cutting edge technologies and staying on the front line of emerging trends and techniques.
  • I am also really looking forward to incorporating the laser into my scar management protocol following surgery."
  • Treatments will be available at Barrett Plastic Surgery starting February 2023.

Advalight Partners with Dr. Jason Emer to Bring the ADVATx to Beverly Hills

Retrieved on: 
Tuesday, November 22, 2022
Fox News, Laser, Telangiectasia, LAS Magazine, Inside Edition, Physician, Skin, Hyperpigmentation, Dermatology, Sensitive, Skin care, News, Melasma, Patient, InStyle, Access Hollywood, TMZ, Technical University of Denmark, Doctor of Philosophy, Scar, Hemangioma, Acne, MD, Burns, Entertainment Tonight, Elective surgery, ELLE, Face, Dyschromia, The New York Times, Rosacea, Self (magazine), Greg Camp, PEOPLE, Institute of technology, Medical device, Cosmetics, Allure

"We are excited to add the ADVATx as an offering to our practice.

Key Points: 
  • "We are excited to add the ADVATx as an offering to our practice.
  • Treatments will be available at Jason Emer, MD | Beverly Hills starting December 8, 2022.
  • Dr. Emer specializes in head-to-toe services: Skin, Laser, Body, Face, Sensitive areas, and is world-famous for his results around sever acne, acne scarring, burns, and traumatic scars.
  • The company is headquartered in Copenhagen, Denmark, and has a sales and service office in San Diego, CA, USA.

Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

Retrieved on: 
Tuesday, August 30, 2022
PPR, COVID-19, NDA, Safety, Securities Exchange Act of 1934, IGA, Securities Act of 1933, Research, NASDAQ, Doxycycline, Entrepreneurship, Independent Women Part I, Data, National Rosacea Society, Telangiectasia, Drug Quality and Security Act, S.A, Minocycline, SEC, Skin, U.S. Securities and Exchange Commission, Patent, Journal, Disorder, GLOBE, Fortress Biotech, Adult, Regulation, Marketing, Dermatology, Laboratory, Annual report, Private Securities Litigation Reform Act, Forward-looking statement, Patient, Pharmaceutical industry, Dietary supplement, Rosacea

The Phase 3 clinical trials are part of a collaboration with Dr. Reddys Laboratories Ltd. for the ongoing development and commercialization of the DFD-29 program.

Key Points: 
  • The Phase 3 clinical trials are part of a collaboration with Dr. Reddys Laboratories Ltd. for the ongoing development and commercialization of the DFD-29 program.
  • In a Phase 2 multicenter clinical trial, DFD-29 achieved nearly double the efficacy compared to doxycycline capsules 40 mg on reducing total inflammatory lesions and Investigators Global Assessment (IGA) treatment success.
  • The MVOR-01 and MVOR-02 clinical trials are randomized in a 3:3:2 ratio to DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg), Oracea (Doxycycline capsules 40 mg) or placebo once daily for 16 weeks.
  • The secondary objective is to evaluate the safety, efficacy and tolerability of DFD-29 compared to Oracea (Doxycycline capsules 40 mg).

ADVALight Partners with Skin Wellness Dermatology Associates to Bring the Gold Standard of Laser Technology To Durham, NC

Retrieved on: 
Monday, May 9, 2022
Melasma, Dermatology, Scar, Acne, Wart, Rosacea, Hemangioma, Laser, Patient, Dyschromia, Skin, FAAD, Greg Camp, Telangiectasia, Petroleum jelly, Medical device, Cosmetics, MD

Travis Mahan, President of ADVALight shared, "We are thrilled to work with Dr. Jackson, aiding in her mission to give patients the best skin they can achieve.

Key Points: 
  • Travis Mahan, President of ADVALight shared, "We are thrilled to work with Dr. Jackson, aiding in her mission to give patients the best skin they can achieve.
  • Dr. Jackson's focus on skin education and innovative treatments makes her and the Skin Wellness Dermatology team a great partner to showcase this easy to use, result driven laser."
  • This treatment will ensure that you'll leave the clinic with a youthful glow to your skin.
  • Treatments will be available at Skin Wellness Dermatology Associates starting May 1st, 2022.

ADVALight Partners with Refresh Dermatology to Bring Gold Standard Laser Technology To Houston, TX

Retrieved on: 
Wednesday, May 4, 2022
Melasma, Dermatology, Scar, Acne, Hyperpigmentation, Wart, Rosacea, Hemangioma, Laser, Physician, Patient, Dyschromia, Refresh, MD, Skin, Greg Camp, Goal, Telangiectasia, Petroleum jelly

NEW YORK, May 4, 2022 /PRNewswire/ --ADVALight, the globally renowned company behind one of the most sophisticated dermatology lasers in the world, the ADVATx, is proud to announce Refresh Dermatology as the newest partner to offer the standard of simple to use, no downtime, non-ablative laser treatments in Houston, TX.

Key Points: 
  • NEW YORK, May 4, 2022 /PRNewswire/ --ADVALight, the globally renowned company behind one of the most sophisticated dermatology lasers in the world, the ADVATx, is proud to announce Refresh Dermatology as the newest partner to offer the standard of simple to use, no downtime, non-ablative laser treatments in Houston, TX.
  • ADVATx from ADVALight combines the industry standard wavelength for eliminating vascular abnormalities with the new gold standard for non-ablative resurfacing allowing physicians and health care providers to treat 25 FDA/CE cleared indications ranging from vascular abnormalities to acne, wrinkle reduction, and warts.
  • The minimal downtime with significant visible results for all skin types make it easy for patients to integrate it into their routine. "
  • Treatments will be available at Refresh Dermatology starting May 5, 2022.